Optimisation des trajectoires en soins en chirurgie au CHUM: évaluation de l’implantation de l’approche ERAS en gynécologie/gynéco-oncologie
Investigatrice principale: Samouëlian V
Organisme: MEDTECH, Fonds de soutien à l’innovation en santé et services sociaux (FSISSS)
Montant: 294 425$
12/2019 – 12/2021 ACTIFS
Exploiting Senescence & Senolytics in high grade serous ovarian cancer (HGSOC) patients
Investigatrice principale: Provencher D Co-Investigateurs: Mes-Masson AM
Organisme: Ovarian Cancer Canada (OCC), OvCAN Priority 3 – Early Phase Clinical Trials with a Translational Emphasis Montant: 1 000 000$
09/2020 – 08/2023
The Quebec Cancer Consortium for Novel Therapeutics and Biomarkers - QCC Agence: Ministère de l’économie et de l’innovation du Québec
Investigateurs principaux: Provencher D, Mes-Masson AM Montant total: 10 000 000$
04/2019-03/2023
Development of small-molecule inhibitors of Ran GTPase as anti-cancer agents Agence : QBCF and IRICoR
Investigatrice principale: Mes-Masson AM Co-investigatrice: Provencher D
Montant: 600 000$
07/2020-10/2023
A multi arm phase I/II basket trial investigating augmentation of apoptosis in high grade serous ovarian cancer (HGSC) and triple negative breast cancer (TNBC) Investigatrice principale: Provencher D
Co-investigatrice: Mes-Masson AM Organisme: Exactis
Montant: 1 000 000$
10/2019-09/2021
Réseau de recherche sur le cancer
Investigatrice principale: Mes-Masson AM Co-investigatrice: Provencher D
Organisme: Fonds de la Recherche en Santé du Québec (FRSQ)
Montant: 4 400 000$
04/2011-07/2021
Targeting genome instability as an essential vulnerability in ovarian cancer
Investigatrice principale: Mes-Masson AM Co-investigatrice: Provencher D
Organisme: Fonds de la Recherche en Santé du Québec (FRSQ) - Oncopole
Montant: 1 500 000$
10/2018-09/2021
Microfiltration of circulating and disseminated tumor cells in ovarian cancer: From monitoring therapeutic response towards predicting disease outcome
Co-investigatrices: Mes-Masson AM, Provencher D Organisme: Canadian Institutes of Health Research (CIHR) Montant: 382 500$/an
08/2018-07/2021
Targeting cellular aneuploidy through modulation of Ran GTPase in epithelial ovarian cancer
Investigateurs principaux: Mes-Masson AM Co-investigatrice: Provencher D
Organisme: Canadian Institutes of Health Research (CIHR) Montant: 802 725$
08/2016-07/2021
The immunoTherapy NeTwork (iTNT)
Co-investigatrices: Mes-Masson AM, Provencher D Organisme: Terry Fox Research Institute (TFRI) Montant: 5 400 000$
01/2018-12/2020
muFO 1. From experimental platform to clinical innovation: empirical drug sensitivity testing for personalized medicine in oncology
Co-investigatrices: Mes-Masson AM, Provencher D Organisme: Institut Transmedtech (ITMT)
Montant: 87 500$
11/2018-10/2020
36
ANNEXE 2
Protocoles actifs CHUM HMR
Ovaires
A Phase III Randomized Study of Phase III Evaluating Hyperthermic Intra- Peritoneal Chemotherapy
(HIPEC) in the Treatment of Relapse Ovarian Cancer CHIPOR X
A Randomized Phase II Double-Blind Placebo-Controlled Trials of Acetylsalicylic Acid (ASA) in
Chemoprevention of Ovarian Cancer with BRCA 1 and 2 Mutations (STICs and STONEs) OV.25 X X Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or
Olaparib alone, or Standard of care chemotherapy in women with recurrent platinumresistant or
-refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS) OVC2 X X
A phase II study of durvalumab and tremelimumab in patients with advanced rare tumours IND228 X A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine
(IMGN853) in Combination with Bevacizumab, Carboplatin, Pegylated GY014Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin, in Adults with Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
FORWARD2 X
A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed,
BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer ARIEL4 X A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rucaparib as Switch
Maintenance Following Platinum-Based Chemotherapy in Patients with Platinum-Sensitive, High-Grade
Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer ARIEL3 X A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients with
Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer NEO X A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients
Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line
Platinum-Based Chemotherapy ATHENA X
MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High- Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian
Tube Cancers with High Folate Receptor-Alpha Expression MIRASOL X
(D081RC00001) Phase III Randomised, Double Blind, Placebo Controlled, Multicentre Study of durvalumab in combination with chemotherapy and bevacizumab followed by maintenance durvalumab, bevacizumab
and olaparib in newly diagnosed advanced ovarian cancer patients DUO-O X
ROSY-O: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with
Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment ROSY-O X X A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance
Retreatment in patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding
to Repeat Platinum Chemotherapy (OReO) OREO X
A randomized, Double-Blind, Phase 3 comparison of platinum-based therapy with TSR 042 and niraparib versus standard of care platinum-based therapy as First line treatment of stage III or IV nonmucinous
Epithelial ovarian cancer FIRST X
OPINION - A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non- Germline BRCA Mutated Ovarian Cancer Patients
who are in Complete or Partial Response Following Platinum based Chemotherapy OPINION X A Randomized Phase 3, Double-Blind Study of chemotherapy With or Without Pembrolizumab Followed
by Maintenance With Olaparib or Placebo for the First- Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC)
MK-7339-ROME X
A PHASE 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients
with Platinum Sensitive Ovarian Cancer NOVA X
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based
Chemotherapy PRIMA X
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian
Cancer following First Line Platinum Based Chemotherapy SOLO1 X
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician’s Choice Single Agent Chemotherapy in the Treatment of
Platinum Sensitive Relapsed Ovarian Cancer in Patients carrying germline BRCA1/2 Mutations SOLO3 X
37
Col
An Open Label, Randomized, Phase 3 Clinical Trial of REGN2810 vs Therapy of Investigator's Choice
Chemotherapy in Recurrent or metastatic Platinum- Refractory Cervical Carcinoma REGENERON X A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple
Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early-Stage Cervical Cancer CX.5 X X Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus
Chemotherapy Versus Chemotherapy Plus Placebo for the First- Line Treatment of Locally Advanced or
Metastatic Cervical Cancer (KEYNOTE- 826) KEYNOTE-826 X
A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to assess the efficacy and safety of Olaparib Monotherapy versus Physician’s Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients carrying germline BRCA1/2 Mutations
KEYNOTE-A18 X
Endomètre
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti- PD-1 Monoclonal
Antibody, in Patients with Advanced Solid Tumors GARNET X
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel for Optimally Debulked Advanced Endometrial Carcinoma
LUNCHBOX X
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib Versus
Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001) LEAP
(MK-7902) X
MK3475 Protocol 775 A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician’s Choice
in Participants with Advanced Endometrial Cancer KEYNOTE-775 X X
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-
042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent
or Primary Advanced Endometrial Cancer (RUBY) RUBY X
38